Safaa Mohamed Gasim Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Safaa Mohamed Gasim Ali has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Almashhadani
Neonatal Intensive Care Unit, Women’s Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar
2 shared publications - Amna Abdelgadir Mohamed
Department of Pediatrics, Hamad General Hospital, Hamad Medical Corporation, Doha 3050, Qatar
2 shared publications - Ashraf Gad
Division of Neonatal-Perinatal Medicine, Women’s Wellness and Research Center, Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar
2 shared publications - Muhammed Talha Hepsen
Department of Pediatrics, Hamad General Hospital, Hamad Medical Corporation, Doha 3050, Qatar
2 shared publications - Nuha Nimeri
Neonatal Intensive Care Unit (NICU), Women’s Wellness and Research Center (WWRC), Hamad Medical Corporation, Doha, QAT
2 shared publications - Omar Haidar
Department of Pediatrics, Hamad General Hospital, Hamad Medical Corporation, Doha 3050, Qatar
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
Early Neonatal Hyperglycemia, Risk Factors, and Adverse Outcomes in Extremely Preterm Infants: A Propensity-Matched Cohort Study
Background: Neonatal hyperglycemia is a common metabolic complication in extremely preterm (EP) infants; however, early risk factors and associated outcomes remain incompletely defined. Objective: To evaluate the association between neonatal hyperglycemia in the first postnatal week and key neonatal morbidities including early neurodevelopmental risk in EP infants. Methods: We conducted a retrospective cohort study of EP infants born in 2018–2019 at the Women’s Wellness and Research Center. Neonatal hyperglycemia was defined as a blood glucose level > 8.3 mmol/L. Maternal factors, delivery room interventions, early physiological markers, neonatal morbidities, and follow-up outcomes were compared. Propensity score matching was applied to balance the baseline demographic and perinatal differences. Results: Among 225 EP infants, 131 (58.2%) developed neonatal hyperglycemia in the first week (mild, 21.4%; moderate, 42%; severe, 36.6%). Before matching, infants with neonatal hyperglycemia had lower gestational age and birth weight and required more delivery-room surfactant, and their mothers had lower rates of premature rupture of membranes. After matching, neonatal hyperglycemia was associated with higher rates of ventilator-associated pneumonia (1.45 vs. 0.37; IRR 6.2, 95% CI 1.4–27.6), longer duration of invasive ventilation (19.8 ± 25.3 vs. 8.9 ± 24.8 days; mean difference −10.9 days; p = 0.042), higher postnatal steroid exposure (18.2% vs. 5.5%; OR 4.6, 95% CI 1.6–14.4; p = 0.040), and severe retinopathy of prematurity (ROP) (21.6% vs. 6.4%; OR 4.0, 95% CI 1.0–15.5; p = 0.032). A trend toward moderate-to-severe bronchopulmonary dysplasia was observed (33.3% vs. 15.9%; p = 0.054). Mortality did not differ significantly between groups; however, among non-survivors, age at death was higher in the neonatal hyperglycemia group. Conclusions: In EP infants, early neonatal hyperglycemia is associated with higher respiratory morbidity and severe ROP even after propensity score matching. These findings support neonatal hyperglycemia as a clinically relevant early risk marker and justify further prospective and interventional studies.
Top Cited PapersOpen AccessEarly Neonatal Hyperglycemia, Risk Factors, and Adverse Outcomes in Extremely Preterm Infants: A Propensity-Matched Cohort Study
Background: Neonatal hyperglycemia is a common metabolic complication in extremely preterm (EP) infants; however, early risk factors and associated outcomes remain incompletely defined. Objective: To evaluate the association between neonatal hyperglycemia in the first postnatal week and key neonatal morbidities including early neurodevelopmental risk in EP infants. Methods: We conducted a retrospective cohort study of EP infants born in 2018–2019 at the Women’s Wellness and Research Center. Neonatal hyperglycemia was defined as a blood glucose level > 8.3 mmol/L. Maternal factors, delivery room interventions, early physiological markers, neonatal morbidities, and follow-up outcomes were compared. Propensity score matching was applied to balance the baseline demographic and perinatal differences. Results: Among 225 EP infants, 131 (58.2%) developed neonatal hyperglycemia in the first week (mild, 21.4%; moderate, 42%; severe, 36.6%). Before matching, infants with neonatal hyperglycemia had lower gestational age and birth weight and required more delivery-room surfactant, and their mothers had lower rates of premature rupture of membranes. After matching, neonatal hyperglycemia was associated with higher rates of ventilator-associated pneumonia (1.45 vs. 0.37; IRR 6.2, 95% CI 1.4–27.6), longer duration of invasive ventilation (19.8 ± 25.3 vs. 8.9 ± 24.8 days; mean difference −10.9 days; p = 0.042), higher postnatal steroid exposure (18.2% vs. 5.5%; OR 4.6, 95% CI 1.6–14.4; p = 0.040), and severe retinopathy of prematurity (ROP) (21.6% vs. 6.4%; OR 4.0, 95% CI 1.0–15.5; p = 0.032). A trend toward moderate-to-severe bronchopulmonary dysplasia was observed (33.3% vs. 15.9%; p = 0.054). Mortality did not differ significantly between groups; however, among non-survivors, age at death was higher in the neonatal hyperglycemia group. Conclusions: In EP infants, early neonatal hyperglycemia is associated with higher respiratory morbidity and severe ROP even after propensity score matching. These findings support neonatal hyperglycemia as a clinically relevant early risk marker and justify further prospective and interventional studies.
- Open Access
- 5 January 2026
- Published by MDPI AG in Preprints.org
Early Neonatal Hyperglycemia, Risk Factors, and Adverse Outcomes in Extremely Preterm Infants: A Propensity-Matched Cohort Study
Background: Neonatal hyperglycemia (NH) is a common metabolic complication among (NH) infants. However, early risk factors and clinical outcomes of NH remain unclear. Objective: To evaluate the association of NH with clinical outcomes and neurodevelopmental(NDD) risk in EP infants. Methods: This retrospective propensity score matching (PSM) study, included EP, born between 2018-2019 at women’s wellness and research Center who met the NH criteria (blood glucose >8.3 mmol/L). Hyperglycemia severity, maternal factors, delivery room interventions, early physiological markers, neonatal morbidities, and follow-up outcomes were compared. Propensity score matching (1:1) was used to adjust for significant baseline demographics and clinical characteristics. Results: Out of 225 EP infants, 131 (58.2%) developed NH in the first week of life of infants, with mild hyperglycemia in 31.0%, moderate in 14.6%, and severe in 11.1% of cases. Before matching, infants with NH were more preterm and had lower birth weight and head circumference. Their mothers had lower rates of premature rupture of membranes (PPROM). Affected infants required more surfactant in the delivery room and had higher oxygen and mechanical ventilation needs during the first week. After matching, NH was associated with significantly higher rates of ventilator-associated pneumonia (VAP), with 23.6% vs 3.7%, OR 8.04 CI: 1.72–37.66, p=0.003, longer duration of mechanical ventilation (19.8±25.3 vs 8.9±24.8 days, MD -10.942, CI -21.470–-0.420, p=0.042), higher postnatal steroid use (18.2% vs 5.5%, OR 4.64, CI 1.56–14.37, p=0.040) After matching, NH was associated with significantly higher rates of severe retinopathy of prematurity (ROP), ( 21.6% vs 6.4%, OR 4.03 CI: 1.04–15.50, p= 0.032).and trend towards moderate to severe bronchopulmonary dysplasia (BPD) (33.3% vs 15.9%, OR 2.64, CI 0.96–7.23, p=0.054). No significant differences in mortality were observed between the groups; however, infants with NH who died were older. Conclusion: Early NH in EP infants is associated with an increased risk of ventilator-associated pneumonia, prolonged mechanical ventilation, severe ROP, and moderate to severe BPD. These findings suggest that NH may contribute to poorer short-term outcomes in this vulnerable population.
- 5 January 2026
- Published by MDPI AG in Preprints.org
Open AccessEarly Neonatal Hyperglycemia, Risk Factors, and Adverse Outcomes in Extremely Preterm Infants: A Propensity-Matched Cohort Study
Background: Neonatal hyperglycemia (NH) is a common metabolic complication among (NH) infants. However, early risk factors and clinical outcomes of NH remain unclear. Objective: To evaluate the association of NH with clinical outcomes and neurodevelopmental(NDD) risk in EP infants. Methods: This retrospective propensity score matching (PSM) study, included EP, born between 2018-2019 at women’s wellness and research Center who met the NH criteria (blood glucose >8.3 mmol/L). Hyperglycemia severity, maternal factors, delivery room interventions, early physiological markers, neonatal morbidities, and follow-up outcomes were compared. Propensity score matching (1:1) was used to adjust for significant baseline demographics and clinical characteristics. Results: Out of 225 EP infants, 131 (58.2%) developed NH in the first week of life of infants, with mild hyperglycemia in 31.0%, moderate in 14.6%, and severe in 11.1% of cases. Before matching, infants with NH were more preterm and had lower birth weight and head circumference. Their mothers had lower rates of premature rupture of membranes (PPROM). Affected infants required more surfactant in the delivery room and had higher oxygen and mechanical ventilation needs during the first week. After matching, NH was associated with significantly higher rates of ventilator-associated pneumonia (VAP), with 23.6% vs 3.7%, OR 8.04 CI: 1.72–37.66, p=0.003, longer duration of mechanical ventilation (19.8±25.3 vs 8.9±24.8 days, MD -10.942, CI -21.470–-0.420, p=0.042), higher postnatal steroid use (18.2% vs 5.5%, OR 4.64, CI 1.56–14.37, p=0.040) After matching, NH was associated with significantly higher rates of severe retinopathy of prematurity (ROP), ( 21.6% vs 6.4%, OR 4.03 CI: 1.04–15.50, p= 0.032).and trend towards moderate to severe bronchopulmonary dysplasia (BPD) (33.3% vs 15.9%, OR 2.64, CI 0.96–7.23, p=0.054). No significant differences in mortality were observed between the groups; however, infants with NH who died were older. Conclusion: Early NH in EP infants is associated with an increased risk of ventilator-associated pneumonia, prolonged mechanical ventilation, severe ROP, and moderate to severe BPD. These findings suggest that NH may contribute to poorer short-term outcomes in this vulnerable population.
- 16 February 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (2) , e263191
Unusual scrotal infection in a neonate
We report a term baby who presented soon after delivery with bilateral tender scrotal swelling with skin discolouration, which was subsequently diagnosed as rapidly progressive cellulitis. The scrotal swelling was treated as cellulitis with a broad spectrum of antibiotics, covering anaerobes, considering the absence of signs and ultrasonographic features of testicular torsion. He also had meconium aspiration pneumonia, complicated by pulmonary hypertension, and required non-invasive oxygen supplementation and intravenous antibiotics. The swelling slowly improved over 2 weeks without complications. In conclusion, early diagnosis and proper antibiotic treatment are essential to prevent the spread of infection and serious complications.
- 16 February 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (2) , e263191
Unusual scrotal infection in a neonate
We report a term baby who presented soon after delivery with bilateral tender scrotal swelling with skin discolouration, which was subsequently diagnosed as rapidly progressive cellulitis. The scrotal swelling was treated as cellulitis with a broad spectrum of antibiotics, covering anaerobes, considering the absence of signs and ultrasonographic features of testicular torsion. He also had meconium aspiration pneumonia, complicated by pulmonary hypertension, and required non-invasive oxygen supplementation and intravenous antibiotics. The swelling slowly improved over 2 weeks without complications. In conclusion, early diagnosis and proper antibiotic treatment are essential to prevent the spread of infection and serious complications.
- Open Access
- 13 September 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-8
Serum cystatin is a useful marker for the diagnosis of acute kidney injury in critically ill children: prospective cohort study
Acute kidney injury (AKI) has been associated with high morbidity and mortality rates among critically ill children. Cystatin C is a protease inhibitor, and studies have shown that it is a promising marker for the early diagnosis of AKI. Our goal in this study was to assess whether serum cystatin C could serve as an accurate marker for the diagnosis of AKI. This prospective study was undertaken in the pediatric intensive care unit at King Abdulaziz University Hospital. Serum creatinine and serum cystatin C levels were both measured in patients on admission (0 h) and at 6, 12, and 24 h after admission. AKI was diagnosed according to the modified pRIFLE criteria. Receiver operating characteristic (ROC) curve analysis was performed to assess the utility of serum cystatin C for diagnosing AKI. A total of 62 patients were enrolled in this study, and 32 were diagnosed with AKI according to the modified pRIFLE criteria (51.4 %). The area under the ROC curve for serum cystatin indicated that it was a good marker for the diagnosis of AKI at 0, 6, 12 and 24 h, with sensitivities of 78, 94, 94 and 83 %, respectively. However, the specificities of serum cystatin C at 0, 6, 12, and 24 h were 57, 57, 60 and 50 %, respectively. The optimal cutoff value was 0.645 mg/L. The area under the ROC for serum creatinine showed sensitivities of 50, 65.4, 69.2 and 57.7 % and specificities of 67.7, 70, 60 and 70 % at 0, 6, 12 and 24 h, respectively. The optimal cutoff value for serum creatinine was 30 μmol/l. Comparisons of ROC curves revealed that serum cystatin C was superior to serum creatinine for the diagnosis of AKI at 12 h (p = 0.03), but no differences were detected at 0, 6 or 24 h. Serum cystatin is a sensitive, but not a specific, marker for the diagnosis of AKI in critically ill children.
- 13 September 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-8
Open AccessSerum cystatin is a useful marker for the diagnosis of acute kidney injury in critically ill children: prospective cohort study
Acute kidney injury (AKI) has been associated with high morbidity and mortality rates among critically ill children. Cystatin C is a protease inhibitor, and studies have shown that it is a promising marker for the early diagnosis of AKI. Our goal in this study was to assess whether serum cystatin C could serve as an accurate marker for the diagnosis of AKI. This prospective study was undertaken in the pediatric intensive care unit at King Abdulaziz University Hospital. Serum creatinine and serum cystatin C levels were both measured in patients on admission (0 h) and at 6, 12, and 24 h after admission. AKI was diagnosed according to the modified pRIFLE criteria. Receiver operating characteristic (ROC) curve analysis was performed to assess the utility of serum cystatin C for diagnosing AKI. A total of 62 patients were enrolled in this study, and 32 were diagnosed with AKI according to the modified pRIFLE criteria (51.4 %). The area under the ROC curve for serum cystatin indicated that it was a good marker for the diagnosis of AKI at 0, 6, 12 and 24 h, with sensitivities of 78, 94, 94 and 83 %, respectively. However, the specificities of serum cystatin C at 0, 6, 12, and 24 h were 57, 57, 60 and 50 %, respectively. The optimal cutoff value was 0.645 mg/L. The area under the ROC for serum creatinine showed sensitivities of 50, 65.4, 69.2 and 57.7 % and specificities of 67.7, 70, 60 and 70 % at 0, 6, 12 and 24 h, respectively. The optimal cutoff value for serum creatinine was 30 μmol/l. Comparisons of ROC curves revealed that serum cystatin C was superior to serum creatinine for the diagnosis of AKI at 12 h (p = 0.03), but no differences were detected at 0, 6 or 24 h. Serum cystatin is a sensitive, but not a specific, marker for the diagnosis of AKI in critically ill children.